Efficacy and toxicity of old and new disease modifying antirheumatic drugs.
作者信息
Tugwell P, Welch V, Suarez-Almazor M, Shea B, Wells G
机构信息
Department of Medicine, Ottawa Hospital-General Campus, LM-12, 501 Smyth Road, Ottawa, Ontario, Canada.
出版信息
Ann Rheum Dis. 2000 Nov;59 Suppl 1(Suppl 1):i32-5. doi: 10.1136/ard.59.suppl_1.i32.
Abstract
摘要
相似文献
1
Efficacy and toxicity of old and new disease modifying antirheumatic drugs.新旧改善病情抗风湿药物的疗效与毒性
Ann Rheum Dis. 2000 Nov;59 Suppl 1(Suppl 1):i32-5. doi: 10.1136/ard.59.suppl_1.i32.
2
[Methotrexate toxicity. Myths and facts].[甲氨蝶呤毒性。误区与事实]
Z Rheumatol. 2011 Feb;70(2):108-13. doi: 10.1007/s00393-010-0687-0.
3
Disease-modifying antirheumatic drugs.改善病情抗风湿药
Curr Opin Rheumatol. 1997 May;9(3):183-90. doi: 10.1097/00002281-199705000-00003.
4
Safety and Effectiveness of Biologic Disease-Modifying Antirheumatic Drugs in Older Patients with Rheumatoid Arthritis: A Prospective Cohort Study.生物制剂类改善病情抗风湿药物在老年类风湿关节炎患者中的安全性和有效性：一项前瞻性队列研究。
Drugs Aging. 2020 Dec;37(12):899-907. doi: 10.1007/s40266-020-00801-x. Epub 2020 Nov 18.
5
2018 update of the APLAR recommendations for treatment of rheumatoid arthritis.《亚太风湿病学联盟类风湿关节炎治疗推荐（2018年更新版）》
Int J Rheum Dis. 2019 Mar;22(3):357-375. doi: 10.1111/1756-185X.13513. Epub 2019 Feb 27.
6
Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.类风湿关节炎和血清阴性关节炎中除甲氨蝶呤之外的改善病情抗风湿药。
Curr Opin Rheumatol. 2008 May;20(3):251-6. doi: 10.1097/BOR.0b013e3282fb7caa.
7
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.阿达木单抗、依那西普、英夫利昔单抗、聚乙二醇化赛妥珠单抗、戈利木单抗、托珠单抗和阿巴西普用于治疗既往未使用改善病情抗风湿药物治疗且仅在传统改善病情抗风湿药物治疗失败后的类风湿关节炎：系统评价和经济学评估。
Health Technol Assess. 2016 Apr;20(35):1-610. doi: 10.3310/hta20350.
8
[Rheumatoid arthritis: milestones in classification and treatment].[类风湿关节炎：分类与治疗的里程碑]
Dtsch Med Wochenschr. 2011 Feb;136(5):203-5. doi: 10.1055/s-0031-1272510. Epub 2011 Jan 26.
9
A clinical and economic review of disease-modifying antirheumatic drugs.改善病情抗风湿药物的临床与经济学综述
Pharmacoeconomics. 2001;19(7):715-28. doi: 10.2165/00019053-200119070-00002.
10
Outstanding issues in use of disease-modifying agents in rheumatoid arthritis.类风湿关节炎中使用病情改善抗风湿药的未决问题。
Lancet. 1999 Jan 23;353(9149):257-8. doi: 10.1016/s0140-6736(05)74938-2.
引用本文的文献
1
Immunology proves a great success for treating systemic autoimmune diseases - a perspective on immunopharmacology: IUPHAR Review 23.免疫学在治疗全身性自身免疫性疾病方面取得了巨大成功——免疫药理学视角：IUPHAR综述23
Br J Pharmacol. 2017 Jul;174(13):1875-1880. doi: 10.1111/bph.13784. Epub 2017 Apr 24.
2
Genetic markers of treatment response in rheumatoid arthritis.类风湿关节炎治疗反应的遗传标志物。
Curr Rheumatol Rep. 2006 Oct;8(5):369-77. doi: 10.1007/s11926-006-0068-5.
本文引用的文献
1
Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.来氟米特与安慰剂和柳氮磺胺吡啶治疗活动性类风湿关节炎的疗效及安全性比较：一项双盲、随机、多中心试验。欧洲来氟米特研究小组
Lancet. 1999 Jan 23;353(9149):259-66. doi: 10.1016/s0140-6736(98)09403-3.
2
Combination therapy in rheumatoid arthritis: updated systematic review.类风湿关节炎的联合治疗：最新系统评价
Br J Rheumatol. 1998 Jun;37(6):612-9. doi: 10.1093/rheumatology/37.6.612.
3
A double-blind controlled study comparing sulphasalazine with placebo in rheumatoid factor (RF)-negative rheumatoid arthritis.一项在类风湿因子（RF）阴性类风湿关节炎患者中比较柳氮磺胺吡啶与安慰剂的双盲对照研究。
Clin Rheumatol. 1995 Sep;14(5):531-6. doi: 10.1007/BF02208150.
4
New classification of antirheumatic drugs. The evolution of a concept.抗风湿药物的新分类。一个概念的演变。
J Rheumatol. 1993 Mar;20(3):585-7.
5
Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study.柳氮磺胺吡啶用于早期类风湿性关节炎。一项为期48周的双盲、前瞻性、安慰剂对照研究。
Arthritis Rheum. 1993 Nov;36(11):1501-9. doi: 10.1002/art.1780361104.
6
Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate.柳氮磺胺吡啶治疗类风湿性关节炎：柳氮磺胺吡啶与安慰剂及金硫代苹果酸钠的双盲对照研究
Br Med J (Clin Res Ed). 1983 Oct 15;287(6399):1102-4. doi: 10.1136/bmj.287.6399.1102.
7
A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis.一项比较柳氮磺胺吡啶、硫代苹果酸金钠和安慰剂治疗类风湿性关节炎的对照试验。
Arthritis Rheum. 1988 Jun;31(6):702-13. doi: 10.1002/art.1780310602.
8
Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials.利用短期疗效/毒性权衡来选择类风湿关节炎的二线药物。已发表临床试验的荟萃分析。
Arthritis Rheum. 1992 Oct;35(10):1117-25. doi: 10.1002/art.1780351003.
Zotero 插件